McKesson Corporation (MCK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, McKesson Corporation (MCK) has a cash flow conversion efficiency ratio of -4.102x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.42 Billion) by net assets ($-834.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See McKesson Corporation (MCK) liquidity interval to measure how many days the company can operate on defensive assets alone.
McKesson Corporation - Cash Flow Conversion Efficiency Trend (1995–2026)
This chart illustrates how McKesson Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
McKesson Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of McKesson Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compagnie Financière Richemont SA
SW:CFR
|
0.084x |
|
CHRISTIAN DIOR ADR1/4/EO2
F:DIO0
|
N/A |
|
Blackstone Group Inc
NYSE:BX
|
0.046x |
|
Glencore plc
MX:GLENN
|
0.089x |
|
Barclays PLC
MX:BCSN
|
N/A |
|
Vertiv Holdings Co
NYSE:VRT
|
0.255x |
|
SK Square Co Ltd
KO:402340
|
0.003x |
|
The Bank of New York Mellon Corporation
NYSE:BK
|
-0.066x |
Annual Cash Flow Conversion Efficiency for McKesson Corporation (1995–2026)
The table below shows the annual cash flow conversion efficiency of McKesson Corporation from 1995 to 2026. For the full company profile with market capitalisation and key ratios, see MCK market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $-834.00 Million | $6.16 Billion | -7.380x | -105.45% |
| 2025-03-31 | $-1.69 Billion | $6.08 Billion | -3.592x | -33.14% |
| 2024-03-31 | $-1.60 Billion | $4.31 Billion | -2.698x | +22.08% |
| 2023-03-31 | $-1.49 Billion | $5.16 Billion | -3.462x | -39.93% |
| 2022-03-31 | $-1.79 Billion | $4.43 Billion | -2.474x | -178.77% |
| 2021-03-31 | $1.45 Billion | $4.54 Billion | 3.141x | +381.93% |
| 2020-03-31 | $6.71 Billion | $4.37 Billion | 0.652x | +56.32% |
| 2019-03-31 | $9.68 Billion | $4.04 Billion | 0.417x | +10.51% |
| 2018-03-31 | $11.52 Billion | $4.34 Billion | 0.377x | +0.21% |
| 2017-03-31 | $12.60 Billion | $4.74 Billion | 0.377x | +6.78% |
| 2016-03-31 | $10.41 Billion | $3.67 Billion | 0.353x | +7.31% |
| 2015-03-31 | $9.47 Billion | $3.11 Billion | 0.329x | +8.11% |
| 2014-03-31 | $10.32 Billion | $3.14 Billion | 0.304x | -13.46% |
| 2013-03-31 | $7.07 Billion | $2.48 Billion | 0.351x | -18.68% |
| 2012-03-31 | $6.83 Billion | $2.95 Billion | 0.432x | +33.36% |
| 2011-03-31 | $7.22 Billion | $2.34 Billion | 0.324x | +5.31% |
| 2010-03-31 | $7.53 Billion | $2.32 Billion | 0.307x | +40.95% |
| 2009-03-31 | $6.19 Billion | $1.35 Billion | 0.218x | +53.66% |
| 2008-03-31 | $6.12 Billion | $869.00 Million | 0.142x | -42.13% |
| 2007-03-31 | $6.27 Billion | $1.54 Billion | 0.245x | -47.19% |
| 2006-03-31 | $5.91 Billion | $2.74 Billion | 0.465x | +59.29% |
| 2005-03-31 | $5.28 Billion | $1.54 Billion | 0.292x | +167.37% |
| 2004-03-31 | $5.17 Billion | $563.40 Million | 0.109x | -25.90% |
| 2003-03-31 | $4.72 Billion | $695.50 Million | 0.147x | +84.89% |
| 2002-03-31 | $4.14 Billion | $329.30 Million | 0.080x | -16.83% |
| 2001-03-31 | $3.69 Billion | $353.10 Million | 0.096x | +186.55% |
| 2000-03-31 | $3.76 Billion | $-416.00 Million | -0.111x | -207.33% |
| 1999-03-31 | $3.08 Billion | $317.10 Million | 0.103x | +7404.23% |
| 1998-03-31 | $1.60 Billion | $2.20 Million | 0.001x | -99.16% |
| 1997-03-31 | $1.46 Billion | $238.10 Million | 0.164x | +7239.94% |
| 1996-03-31 | $1.12 Billion | $2.50 Million | 0.002x | -98.77% |
| 1995-03-31 | $1.07 Billion | $195.10 Million | 0.182x | -- |
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; d… Read more